Related Experiment Video

Updated: May 20, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

Hsiao-Ping Chen1, Jeng-Jer Shieh, Chia-Che Chang

  • 1Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.

Gut
|July 10, 2012
PubMed
Abstract

Insights

Metformin use significantly reduces hepatocellular carcinoma (HCC) risk in type 2 diabetes patients. This common diabetes drug inhibits cancer cell growth and promotes cell cycle arrest, offering a potential antitumoural effect.

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Diabetes mellitus management
  • Cancer chemoprevention

Background:

  • Type 2 diabetes mellitus (T2DM) increases hepatocellular carcinoma (HCC) risk.
  • Metformin, a T2DM drug, may attenuate this risk.
  • The antitumoural effects of metformin on hepatocarcinoma cells are not well-studied.

Purpose of the Study:

  • To investigate the chemopreventive effects of metformin on HCC risk in diabetic patients.
  • To explore the antitumoural mechanisms of metformin in hepatoma cell lines.

Main Methods:

  • Nationwide case-control study (97,430 HCC patients, 19,860 matched controls).
  • Multivariate and stratified analyses to examine metformin's chemopreventive effects.
  • In vitro studies on HepG2 and Hep3B cell lines to assess metformin's impact on cell proliferation and cell cycle.

Main Results:

  • Diabetes is associated with a 2.29-fold increased risk of HCC.
  • Each year of metformin use reduced HCC risk by 7% in diabetic patients (adjusted OR=0.93).
  • Metformin inhibited hepatoma cell proliferation and induced G0/G1 cell cycle arrest via AMPK/LKB1 pathway, upregulating p21/p27 and downregulating cyclin D1.

Conclusions:

  • Metformin use is dose-dependently associated with decreased HCC risk in diabetic patients.
  • Metformin exerts antitumoural effects by inhibiting hepatoma cell proliferation.
  • Metformin induces cell cycle arrest at the G0/G1 phase, contributing to its protective role against HCC.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...